Establishment and Characterization of Rat Portal Myofibroblast Cell Lines

Michel Fausther¹,² *, Jessica R. Goree¹,², Élise G. Lavoie¹,², Alicia L. Graham¹, Jean Sévigny³,⁴, Jonathan A. Dranoff¹,²

¹ Division of Gastroenterology & Hepatology, University of Arkansas for Medical Sciences, Little Rock, AR, United States of America, ² Research Service, Central Arkansas VA Healthcare System, Little Rock, AR, United States of America, ³ Département de Microbiologie-Infectiologie et d’Immunologie, Faculté de Médecine, Université Laval, QC, Canada, ⁴ Centre de Recherche du CHU de Québec, QC, Canada

* mfausther@uams.edu

Abstract

The major sources of scar-forming myofibroblasts during liver fibrosis are activated hepatic stellate cells (HSC) and portal fibroblasts (PF). In contrast to well-characterized HSC, PF remain understudied and poorly defined. This is largely due to the facts that isolation of rodent PF for functional studies is technically challenging and that PF cell lines had not been established. To address this, we have generated two polyclonal portal myofibroblast cell lines, RGF and RGF-N2. RGF and RGF-N2 were established from primary PF isolated from adult rat livers that underwent culture activation and subsequent SV40-mediated immortalization. Specifically, Ntpdase2/Cd39l1-sorted primary PF were used to generate the RGF-N2 cell line. Both cell lines were functionally characterized by RT-PCR, immunofluorescence, immunoblot and bromodeoxyuridine-based proliferation assay. First, immortalized RGF and RGF-N2 cells are positive for phenotypic myofibroblast markers alpha smooth muscle actin, type I collagen alpha-1, tissue inhibitor of metalloproteinases-1, PF-specific markers elastin, type XV collagen alpha-1 and Ntpdase2/Cd39l1, and mesenchymal cell marker ecto-5’-nucleotidase/Cd73, while negative for HSC-specific markers desmin and lecithin retinol acyltransferase. Second, both RGF and RGF-N2 cell lines are readily transfectable using standard methods. Finally, immortalized RGF and RGF-N2 cells attenuate the growth of Mz-ChA-1 cholangiocarcinoma cells in co-culture, as previously demonstrated for primary PF. Immortalized rat portal myofibroblast RGF and RGF-N2 cell lines express typical markers of activated PF-derived myofibroblasts, are suitable for DNA transfection, and can effectively inhibit cholangiocyte proliferation. Both RGF and RGF-N2 cell lines represent novel in vitro cellular models for the functional studies of portal (myo)fibroblasts and their contribution to the progression of liver fibrosis.

Introduction

Portal fibroblasts (PF) are defined as resident spindle-shaped fibroblasts found in the portal mesenchyme, with a peribiliary distribution[1]. During liver homeostasis, PF are involved in
the maintenance of bile duct cell mass and the synthesis of extracellular matrix proteins[2–4]. Following liver injury leading to development of fibrosis, PF undergo myofibroblastic differentiation, phenotypically transitioning from quiescence to an “activated” state[5]. During this critical process, PF acquire contractile properties mainly through expression of lpha-smooth muscle actin (αSMA) and exhibit increased fibrogenic activity through production and release of fibrillar collagens. Expression of αSMA and release of collagen have been seen as indicators of myofibroblastic differentiation/activation. Indeed, recent fate mapping studies clearly indicate that, similar (although to a lesser extent) to hepatic stellate cells (HSC), PF represent cellular precursors of myofibroblasts during liver fibrosis[6,7]. Importantly, the contribution of PF to liver fibrosis is thought to be of particular importance in cholestatic liver injury but less so in hepatocellular injury[8]. However, the functions of PF in liver health and disease remain poorly defined and understudied. In that regard, a contributing factor is certainly the lack of in vitro models for portal (myo)fibroblasts. In contrast, a plethora of in vitro models to study HSC from human and murine species are available: human LX-1[9], LX-2[9], and hTERT[10] cell lines, mouse GRX[11] and JS1[12] cell lines, and rat HSC-T6[13] and CFSC[14] cell lines have been described, yet no immortalized portal (myo)fibroblast have been reported to date. Moreover, primary rodent PF isolation methods remain feasible but challenging due to variability in cell numbers, purity, viability, and growth capacity. To address this issue, we sought to establish PF cell lines via SV40 large T antigen-mediated immortalization of primary isolated rat PF. We describe, in the present report, the generation and characterization of two immortalized rat portal myofibroblast cell lines, RGF and RGF-N2 generated using this approach.

Methods

Materials and Reagents

Cell culture reagents and media were obtained from Life Technologies (Life Technologies, Carlsbad, CA). Molecular biology reagents and kits were obtained from Life Technologies and Qiagen (Qiagen, Valencia, CA). All other reagents and chemicals were of the highest quality available.

Animal Care

All rat experiments were performed in accordance with regulations approved by the University of Arkansas for Medical Sciences Institutional Animal Care and Use Committee. Male Sprague-Dawley rats (12 weeks/400 g) were purchased from Charles River Laboratories (Redfield, AR) and used for two-step collagenase liver perfusion protocol[15,16].

Isolation of Rat Portal Fibroblasts

Primary PF were isolated from freshly perfused livers of healthy rats, as previously described [15,16]. The liver was perfused through the portal vein with Hank’s Balanced Salt Solution (HBSS) minus Ca²⁺/Mg²⁺ buffer (Life Technologies) supplemented with heparin (Fresenius Kabi, Lake Zurich, IL) for blanching. Upon inferior vena cava transection to allow blood and fluid drainage, the liver was further perfused with HBSS buffer minus Ca²⁺/Mg²⁺ alone, then with a collagenase (type 2 blend) solution (Worthington Biochemical, Lakewood, NJ) in HBSS plus Ca²⁺/Mg²⁺ buffer. The liver was then removed from the rat and triturated in cold Leibovitz’s media (Life Technologies), to tease away parenchymal cells from the biliary tree. The recovered hilar remnants were further digested in a solution of pronase (Roche, Indianapolis, IN) in Dulbecco’s modified Eagle’s medium/F-12 media (DMEM/F-12, Life Technologies) supplemented with type 2 collagenase and DNAse (Sigma-Aldrich), followed by mesh filtration.
(40-micron cell strainer, Corning Life Sciences, Tewksbury, MA). The remaining pronase-resistant hilar remnants were recovered and further digested in a solution of hyaluronidase (Sigma-Aldrich, St-Louis, MO) in DMEM/F-12 media supplemented with type 2 collagenase and DNAse, again followed by mesh filtration. The liberated cells from both pronase and hyaluronidase digestion steps were combined and washed with a solution of DNAse in RPMI 1640 media (Life Technologies). Finally, the resulting cell suspensions of non-parenchymal cells (mainly portal fibroblasts) were plated in medium containing Dulbecco’s modified Eagle’s medium/F-12 supplemented with 10% fetal bovine serum, 2% penicillin-streptomycin, 0.3% gentamycin, and 0.1% fungizone (Life Technologies).

Immortalization of Rat Portal Fibroblasts

Primary isolated rat PF were grown on plastic for 2 days before media change, and then passed every 4 days twice, at which time cell purity approaches 100% and myofibroblastic differentiation is observed (S1 Fig., PRIMARY PF)[15]. To immortalize primary isolated portal myofibroblasts, cells were transfected with 5 micrograms of a SV40 large T Antigen mammalian expression vector (Addgene plasmid #21826 generated by Dr. David Ron, and obtained from Addgene, Cambridge, MA) using Fugene6 transfection reagent (Promega, Madison, WI). After transfection, cells were grown to confluence and then serially passaged for selection. Cell pools were expanded into RGF and RGF-N2 cell lines and passaged at least 45 times, before analysis (S1 Fig., RGF and RGF-N2). In the case of RGF-N2 cell line, primary isolated cells were sorted before plating and immortalization, using a rabbit polyclonal antibody raised against PF marker rat Ntpdase2 (rN2-6L, Ectonucleotidases-Ab, Quebec, QC, Canada)[17] pre-labeled with Alexa Fluor 488 dye from a Zenon Rabbit IgG Labeling Kit (Life Technologies) according to the manufacturer’s instructions alone, or in combination with a mouse monoclonal antibody raised against rat Thy1.1+[18] coupled to PerCP-Cy5.5 dye (clone HIS51, Life Technologies) (S2 Fig.). In all sorting experiments, propidium iodide (Life Technologies) was used for live cell labeling.

Gene Expression Analysis

Total RNA extractions were performed from rat liver tissue, primary isolated PFs, and SV40-immortalized RGF and RGF-N2 PFs, using a RNeasy Plus Kit (Qiagen). Quantification of total RNA concentration was performed using the Qubit RNA Assay Kit with a Qubit 2.0 Fluorometer (Life Technologies). Treatment of isolated total RNA samples with RNAse-free Ambion DNAse1 enzyme (Life Technologies) was performed to remove any genomic DNA contamination. Complementary DNA (cDNA) synthesis reaction was performed using the iScript Reverse Transcription Supermix (Bio-Rad Laboratories, Hercules, CA). Primary and immortalized cell cDNA reaction products were further used as templates for polymerase chain reaction (PCR) amplification with the TopTaq Master Mix Kit (Qiagen). Target-specific PCR primers sets (Integrated DNA Technologies—IDT, Coralville, IA) were designed using NCBI’s Primer-BLAST program[19] and are listed in Table 1. The following PCR protocol was used: initial denaturation step at 94°C for 3 minutes, followed 35 repetitions of a 3-step cycling program consisting of 30 seconds at 94°C (denaturation), 30 seconds at 60°C (primer annealing), and 30 seconds at 72°C (elongation), and final extension step of 10 minutes at 72°Celsius. Amplification products were visualized on 1% (w/v) agarose (Life Technologies) gels containing 0.5 microgram per milliliter of ethidium bromide nucleic acid stain (Bio-Rad Laboratories) (Fig. 1). Primary and immortalized cell cDNA reaction products (dilution 1:5 in nuclease-free water) were also used as templates for quantitative PCR amplification with the SsoAdvanced Universal Real-Time PCR Supermix (Bio-Rad Laboratories) and validated specific probes for
Table 1. Sequences of primer sets used for gene expression analysis by PCR.

| GENE NAME                                | ACCESSION NUMBER | PRIMER SEQUENCES                     | PRODUCT SIZE (BP) |
|------------------------------------------|------------------|--------------------------------------|-------------------|
| CYTOSKELETON                             |                  |                                      |                   |
| Alpha-smooth muscle actin (αSMA)         | NM_031004.2      | 5'-GCCATCAGGAACCTCGAGAA-3' 5'-AGTTGGTGTAGATGCCGGTG-3' | 273              |
| Elastin (Eln)                            | NM_012722.1      | 5'-CAGGAGTCAAGGCCAAGTT-3' 5'-CTGTTCCACCCAGCACTAA-3' | 665              |
| Desmin (Des)                             | NM_022531.1      | 5'-CAGGAGTCAAGGCCAAGTT-3' 5'-CTGTTCCACCCAGCACTAA-3' | 180              |
| Vimentin (Vim)                           | NM_031140.1      | 5'-GCCATCAGGAACCTCGAGAA-3' 5'-AGTTGGTGATGATGCCGTGT-3' | 467              |
| Glial fibrillary acidic protein (Gfap)    | NM_017009.2      | 5'-GCCATCAGGAACCTCGAGAA-3' 5'-AGTTGGTGATGATGCCGTGT-3' | 467              |
| EXTRACELLULAR MATRIX                     |                  |                                      |                   |
| Type XV collagen alpha-1 (Col15α1)       | NM_001100535.1   | 5'-CGTGTCCGAGATGGTTGGAA-3' 5'-CCGCACAACTGTGGAGAGAT-3' | 297              |
| Type I collagen alpha-1 (Col1α1)         | NM_053304.1      | 5'-CGTGTCCGAGATGGTTGGAA-3' 5'-CCGCACAACTGTGGAGAGAT-3' | 627              |
| Matrix metallopeptidase-9 (Mmp-9)        | NM_031055.1      | 5'-GCCATCAGGAACCTCGAGAA-3' 5'-AGTTGGTGATGATGCCGTGT-3' | 271              |
| Timp metallopeptidase inhibitor 1 (Timp1)| NM_053819.1      | 5'-GCCATCAGGAACCTCGAGAA-3' 5'-AGTTGGTGATGATGCCGTGT-3' | 237              |
| Fibulin-2 (Fbn2)                         | XM_006224990.1   | 5'-GCCATCAGGAACCTCGAGAA-3' 5'-AGTTGGTGATGATGCCGTGT-3' | 455              |
| Lysyl oxidase (Lox)                      | NM_017061.2      | 5'-GCCATCAGGAACCTCGAGAA-3' 5'-AGTTGGTGATGATGCCGTGT-3' | 656              |
| Lysyl oxidase-like 1 (Lox1f)             | NM_001012125.1   | 5'-GCCATCAGGAACCTCGAGAA-3' 5'-AGTTGGTGATGATGCCGTGT-3' | 610              |
| Lysyl oxidase-like 2 (Lox1f)             | NM_001106047.2   | 5'-GCCATCAGGAACCTCGAGAA-3' 5'-AGTTGGTGATGATGCCGTGT-3' | 359              |
| Lysyl oxidase-like 3 (Lox1f)             | NM_001107866.2   | 5'-GCCATCAGGAACCTCGAGAA-3' 5'-AGTTGGTGATGATGCCGTGT-3' | 426              |
| Lysyl oxidase-like 4 (Lox1f)             | NM_001107592.1   | 5'-GCCATCAGGAACCTCGAGAA-3' 5'-AGTTGGTGATGATGCCGTGT-3' | 464              |
| SURFACE MOLECULES                        |                  |                                      |                   |
| Cd9 molecule (Cd9)                       | NM_053018.1      | 5'-GGAGCCCCAGCTGGATAGGACC-3' 5'-CGTGAAATGGTGACTAGGG-3' | 137              |
| Ecotnucleoside triphosphate diphosphohydrolase 2 (Entpd2) | NM_172030.1 | 5'-GCCATCAGGAACCTCGAGAA-3' 5'-AGTTGGTGATGATGCCGTGT-3' | 151              |
| 5' nucleotidase, ecto (Nt5e)             | NM_021576.2      | 5'-GCCATCAGGAACCTCGAGAA-3' 5'-AGTTGGTGATGATGCCGTGT-3' | 151              |
| Cd200 molecule (Cd200)                   | NM_031518.2      | 5'-GCCATCAGGAACCTCGAGAA-3' 5'-AGTTGGTGATGATGCCGTGT-3' | 980              |
| Alkaline phosphatase, liver/bone/kidney  | NM_013059.1      | 5'-GCCATCAGGAACCTCGAGAA-3' 5'-AGTTGGTGATGATGCCGTGT-3' | 735              |
| SIGNAL TRANSDUCTION                      |                  |                                      |                   |
| Platelet-derived growth factor receptor,  | NM_031525.1      | 5'-GCCATCAGGAACCTCGAGAA-3' 5'-AGTTGGTGATGATGCCGTGT-3' | 521              |
| beta polypeptide (Pdgfrβ)                |                  |                                      |                   |
| Transforming growth factor beta, receptor | NM_012775.2      | 5'-GCCATCAGGAACCTCGAGAA-3' 5'-AGTTGGTGATGATGCCGTGT-3' | 521              |
| 1 (Tgfβ1)                                |                  |                                      |                   |
| Vascular endothelium growth factor       | NM_013062.1      | 5'-GCCATCAGGAACCTCGAGAA-3' 5'-AGTTGGTGATGATGCCGTGT-3' | 207              |
| receptor 2 (Vegfr2)                      |                  |                                      |                   |
| Epidermal growth factor receptor (Egfr)  | NM_031507.1      | 5'-GCCATCAGGAACCTCGAGAA-3' 5'-AGTTGGTGATGATGCCGTGT-3' | 587              |

(Continued)
Acta2 (αSMA, Taqman#Rn01759928_g1), Eln (Elastin, IDT#Rn.PT.58.8283578), Collα1 (type I collagen alpha-1, IDT#Rn.PT.58.11414207), Entpd2 (ectonucleoside triphosphate diphosphohydrolase 2, IDT#Rn.PT.58.37204991.g), Nt5e (ecto-5' nucleotidase, IDT#Rn.PT.58.14072388), and housekeeping B2m (beta-2-microglobulin, DT#Rn.PT.58.11709934) and Hprt1 (hypoxanthine phosphoribosyltransferase 1, IDT#Rn.PT.39a.22214832) genes in rat species. The following PCR protocol was used: initial denaturation step at 95°C for 3 minutes, followed 40 repetitions of a 2-step cycling program consisting of 10 seconds at 95°C, 30 seconds at 55 or 57°C.

Immunoblot

Immortalized rat HSC-T6 liver stellate cells[13], and human Mz-Cha-1 cholangiocarcinoma cells[20] cells were grown as described previously. Confluent RGF, RGF-N2, HSC-T6 and Mz-Cha-1 cells were scraped and lysed with RIPA buffer (Thermo Scientific, Rockford, IL) supplemented with Halt Protease and Phosphatase Inhibitor cocktails (Thermo Scientific) for 5 min. Cell lysates were obtained after centrifugation at 14,000 x g for 15 min, and protein concentration was determined with the BCA Protein Assay kit (Thermo Scientific) using bovine serum albumin (BSA) as standard. Proteins (40 g per well) were resolved by SDS-PAGE under reducing conditions, and transferred onto a polyvinylidene difluoride membrane (Immobilon/Millipore, Bedford, MA). Membranes were blocked with 5% Carnation skimmed milk in 1X Phosphate-Buffered Saline (PBS) or 1X Tris-Buffered Saline (TBS), incubated with the following primary antibodies (diluted in 5% BSA in 1X PBS or 1X TBS): mouse monoclonal anti-pan

Table 1. (Continued)

| GENE NAME | ACCESSION NUMBER | PRIMER SEQUENCES | PRODUCT SIZE (BP) |
|-----------|------------------|-----------------|------------------|
| LMNA      | NM_052807.2      | 5'-ATCCGCGGAGCAGAATAACAT-3' 5'-ACGGAGATGGGTTTCCA-3' | 696              |
| Tumor necrosis factor receptor superfamily, member 1a (Tnfrs1a) | NM_013091.1 | 5'-TGAGGAGCCCTACCTGATT-3' 5'-TTCCTTTGGACCTTGGT-3' | 375              |
| Tumor necrosis factor receptor superfamily, member 1b (Tnfrs1b) | NM_130426.4 | 5'-GCCCAACACACATCCCTCCT-3' 5'-GCCAACATGTTCTGTTG-3' | 199              |
| Interleukin 4 receptor (Il4r) | NM_133380.2 | 5'-AAACACACAGCTGAGGAGG-3' 5'-GGTTGAGCTGGAAGCTC-3' | 677              |
| Interleukin 13 receptor, α1 (Il13ra1) | NM_145789.2 | 5'-TGAGTCTGCTGAGCCAAC-3' 5'-GGAGGCCAGTACTATGG-3' | 315              |
| G protein-coupled bile acid receptor 1 (Gpbar1) | NM_177936.1 | 5'-TCAGTCTTGGCCTATGAGG-3' 5'-CTTGTAGCCACCTTGGGCA-3' | 163              |
| Lecithin-retinol acyltransferase (Lrat) | NM_022280.2 | 5'-TGGTCTCAACAAACGCTCTC-3' 5'-AGTACGGTGAGGGGTCAG-3' | 199              |
| Cytoglobin (Ctgb) | NM_130744.2 | 5'-CCTCCAACGACAAGTGGAA-3' 5'-AAGTCAGCCTTGTGGCCCAA-3' | 286              |
| Albumin (Alb) | NM_134326.2 | 5'-GTAGAGCGAGAGGCTACCA-3' 5'-CTGTGTTACACTTCAGCAG-3' | 277              |
| Keratin 19 (Krt19) | NM_199498.1 | 5'-AGGAGCCGTTGAGGATTGTTA-3' 5'-TGAGGTTCTCAAATGTTGGC-3' | 272              |
| EGF-like module containing mucin-like hormone receptor-like 1 | NM_001007557.1 | 5'-CCTTCTGGTTTCTGTGAGCAG-3' 5'-ATGACTGTCAGACTGCTGGCCC-3' | 418              |
| Mesothelin (Msln) | NM_031658.1 | 5'-GTGGTGTTGAATGGAGGTTG-3' 5'-GGATGTGCTGTGGACAATGGA-3' | 857              |

doi:10.1371/journal.pone.0121161.t001
Fig 1. Phenotypic characterization of immortalized rat portal fibroblastic RGF and RGF-N2 cell lines by RT-PCR. (A) Cultured primary isolated aPF (8 days) and immortalized rat PF RGF and RGF-N2 cDNA samples were used as templates in PCR reactions with primers specific to transcripts of several fibrogenic genes in liver myofibroblasts (see Table 1 for gene list and accession numbers). RGF and RGF-N2 cell lines express classical αSMA (Acta2), type I collagen α1 (Col1α1) liver myofibroblast gene products, along with PF-derived elastin (Eln), type XV collagen α1 (Col15α1), and Ntpdase2 (Entpd2) myofibroblast markers, also found in primary culture-activated portal myofibroblasts. Both cell lines are devoid of HSC-derived myofibroblastic desmin (Des) and lecithin-retinol acyl transferase (Lrat) markers. Rat normal liver or brain cDNA was used as positive control, when no PCR amplicon was detected (not shown). Nuclease-free water was used as negative control (not shown). MW, molecular weight; bp, base pairs. (B) Cultured primary isolated aPF (8 days, 2 primary cell isolations) and immortalized rat PF RGF (passages #61 and #64) and RGF-N2 cDNA (passages #54 and #55) samples were used as templates in quantitative PCR reactions with probes specific to transcripts of fibrogenic Acta2, Eln, Col1α1, Entpd2, and Nt5e genes in liver myofibroblasts. Housekeeping B2m and Hprt1 genes were separately used as references.

doi:10.1371/journal.pone.0121161.g001
cytokeratin (clone C-11, Sigma-Aldrich) and anti-glial fibrillary acidic protein (clone GA5, Cell Signaling, Danvers, MA) antibodies or rabbit polyclonal: anti-αSMA (ab#5694, Abcam, Cambridge, MA), anti-elastin antibody (CL55041AP, Cedarlane Immunologicals), anti-platelet derived growth factor receptor, beta polypeptide (clone#958, Abcam), anti-epidermal growth factor receptor (#PA1-1110, Thermo Scientific), and anti-glyceraldehyde-3-phosphate dehydrogenase (#G9545, Sigma-Aldrich) antibodies, followed by appropriate Molecular Probes goat Alexa Fluor-conjugated anti-mouse IgG and Fluor-conjugated anti-rabbit IgG antibodies (diluted in 0.5% Milk in 1X PBS or 1X TBS), and bands were visualized by use of a Typhoon imaging system (GE Healthcare Bio-Sciences, Pittsburgh, PA) (Fig. 2).

Immunofluorescence Microscopy

Immortalized rat RGF and RGF-N2 PF were fixed with neutral 4% paraformaldehyde (PFA) solution (diluted in 1X PBS, pH = 7.2) for 15 min at room temperature and washed in 1X PBS. Fixed cells were then incubated with the following mouse monoclonal antibodies: anti-β-actin (clone AC15, Sigma-Aldrich), anti-rat Cd73 (clone 5F/B9, BD Pharmingen, San Diego, CA), anti-αSMA (clone 1B4, Sigma-Aldrich), anti-simian virus SV40 T antigen (clone Pab101, Santa Cruz Biotechnology, Dallas, TX), and rabbit polyclonal antibodies: anti-rat Ntpdase2 (rN2-6L, Ectonucleotidases-Ab) and anti-rat elastin (CL55041AP, Cedarlane Immunologicals, Westbury, NY), overnight at 4°C. Slides were washed 3 times with 1X PBS, then incubated with appropriate Molecular Probes goat Alexa Fluor-conjugated anti-mouse IgG and anti-rabbit
IgG antibodies (Life Technologies) for 1 h at room temperature. Slides were washed 3 times with 1X PBS, 1 time with deionized water, and subsequently mounted in ProLong Gold Anti-fade reagent with 4,6-diamidino-2-phenylindole (DAPI) nuclear stain medium (Life Technologies). Slides incubated with secondary antibody alone were used as a control for specificity of fluorescence detection. Confocal fluorescence microscopy images were acquired using Zeiss LSM 510 Meta imaging system (Zeiss Laboratories, White Plains, NY) (Fig. 3).

Transfection Assay

Immortalized RGF and RGF-N2 cells (2.5 x 10^4) were transfected immediately after trypsinization with a monomeric GFP (mGFP) mammalian expression vector (Addgene plasmid #18696, generated by Dr. Karel Svoboda) using Fugene6 transfection reagent (Promega) at 1:3 (microgram(s) of DNA/microliter(s) of reagent) ratio or Lipofectamine2000 at 1:6 ratio, and
grown for 48 h. Transfected cells were then fixed in neutral 4% PFA solution, washed in 1X PBS, and mounted in ProLong Gold Anti-fade reagent with DAPI, prior to confocal fluorescence microscopy imaging (Fig. 4).

Co-Culture Assay

Immortalized Mz-ChA-1 cells were grown in DMEM-high glucose supplemented with 10% fetal bovine serum, 2% penicillin-streptomycin and used for co-culture assays with RGF or RGF-N2 cells (n = 4 for each PF cell line), as previously described[21]. All cell lines were plated and grown to confluence in individual cell culture dishes, before use. On day 1, Mz-ChA-1 cells (10 x 10^3 cells count per well, in triplicate) were plated in individual wells of 6-well plates and overlaid with culture media containing bromodeoxyuridine-labeling reagent from a commercial cell proliferation kit (Roche Diagnostics, Indianapolis, IN) for a 24-hour period, to allow incorporation. On day 2, RGF and RGF-N2 cells were added (20 x 10^3 cells count per well) at an estimated 2:1 ratio to RGF and RGF-N2 cells, as previously described. Both Mz-ChA-1 and RGF or RGF-N2 cells were maintained in co-culture for an additional 24-hour period, in DMEM-high glucose supplemented with 10% fetal calf serum, 2% penicillin-streptomycin. On day 3, proliferation rate of Mz-ChA-1 cells was assessed by ELISA, according to the manufacturer’s instructions (Roche Biosciences). Primary isolated rat PFs were used as experimental control cells (not shown). Labeled Mz-ChA-1 cells grown alone were included as baseline controls (Fig. 5).

Statistical methods

Statistical analysis was performed using one-way ANOVA followed by Bonferroni’s post-hoc multiple comparisons test. P-value was considered significant, when P < 0.05.
Results

To generate the immortalized rat PF cell lines, we first isolated primary rat PF from livers of healthy rats. Primary isolated cells were either immediately plated in the case of RGF cell line, or used for cell staining/sorting before plating in the case of RGF-N2 cell line. Based on published literature, ectonucleoside triphosphate diphosphohydrolase 2/Ntpdase2 (Entpd2/Cd39l1) and Thy1.1+ (Cd90/Thy1a) markers were used for cell sorting and enrichment of PF from primary isolated cell preparation pools[17,18]. In one set of experiments, sorting was performed using an Alexa 488 Zenon-coupled rabbit polyclonal antibody directed against rat Ntpdase2, which selectively stained approximately one third of primary isolated cell preparation (S2 Fig., NTPDase2) and Thy1.1+ (Cd90.1/Thy1a) markers were used for cell sorting and enrichment of PF from primary isolated cell preparation pools[17,18]. In one set of experiments, sorting was performed using an Alexa 488 Zenon-coupled rabbit polyclonal antibody directed against rat Ntpdase2, which selectively stained approximately one third of primary isolated cell preparation (S2 Fig., NTPDase2) and Thy1.1+ (Cd90.1/Thy1a) markers were used for cell sorting and enrichment of PF from primary isolated cell preparation pools[17,18]. In one set of experiments, sorting was performed using an Alexa 488 Zenon-coupled rabbit polyclonal antibody directed against rat Ntpdase2, which selectively stained approximately one third of primary isolated cell preparation (S2 Fig., NTPDase2) and Thy1.1+ (Cd90.1/Thy1a) markers were used for cell sorting and enrichment of PF from primary isolated cell preparation pools[17,18]. In one set of experiments, sorting was performed using an Alexa 488 Zenon-coupled rabbit polyclonal antibody directed against rat Ntpdase2, which selectively stained approximately one third of primary isolated cell preparation (S2 Fig., NTPDase2) and Thy1.1+ (Cd90.1/Thy1a) markers were used for cell sorting and enrichment of PF from primary isolated cell preparation pools[17,18]. In one set of experiments, sorting was performed using an Alexa 488 Zenon-coupled rabbit polyclonal antibody directed against rat Ntpdase2, which selectively stained approximately one third of primary isolated cell preparation (S2 Fig., NTPDase2) and Thy1.1+ (Cd90.1/Thy1a) markers were used for cell sorting and enrichment of PF from primary isolated cell preparation pools[17,18]. In one set of experiments, sorting was performed using an Alexa 488 Zenon-coupled rabbit polyclonal antibody directed against rat Ntpdase2, which selectively stained approximately one third of primary isolated cell preparation (S2 Fig., NTPDase2) and Thy1.1+ (Cd90.1/Thy1a) markers were used for cell sorting and enrichment of PF from primary isolated cell preparation pools[17,18].
(Fig. 1A). Primary isolated aPF cells together with RGF and RGF-N2 cells produce mRNAs for PF-specific elastin (Eln) [5,25], fibulin-2 (Fbln2) [26], type XV collagen alpha-1 (Col15a1) [27], lysyl oxidase (Lox), and lysyl oxidase-like 1–4 (Loxl–4) [28] markers. Mmp-9 mRNA expression was robust in primary isolated aPF cells but weak in both RGF and RGF-N2 cell lines. In addition, expression of specific markers for liver myofibroblasts such as, Cytoglobin (Cygb) [29], along with intermediate filaments Vimentin (Vim) [30], Glial fibrillary acidic protein (Gfap) [31] mRNAs was observed, the latter being absent in primary isolated aPF cells. Importantly, primary isolated aPF, RGF, and RGF-N2 cells lack expression (or express negligible levels) of established hepatic stellate cell (HSC)-specific Desmin (Des) and Lecithin-retinol acyltransferase (Lrat) [7] markers. Expression of purinergic cell-surface Ntpdase2, Ecto-5'-nucleotidase/Cd73 (Nt5e) and Tissue non-specific alkaline phosphatase (Alpl) enzymes mRNAs was also detected. Both RGF and RGF-N2 also express several key receptors for signal transduction in myofibroblasts [8,32] including Platelet-derived growth factor receptor, beta polypeptide (Pdgfrβ/Cd140b), Transforming growth factor, beta receptor 1 (Tgfbr1/Alk5), Epidermal growth factor receptor (Egfr), Insulin growth factor 1 receptor (Igf1r/Cd221), and Tumor necrosis factor receptor superfamily 1a (Tnfrs1a/Cd120a) and 1b (Tnfrs1b/Cd120b) members. Moreover, Interleukin-4 receptor alpha (Il-4rα/Cd124), Interleukin-13 receptor, alpha 1 (Il-13rα1/Cd213A1), Cd200 (Mox2), and Cd9 gene products were also detected. Interestingly, expression of Vascular endothelium growth factor receptor-2 (Vegfr2/Cd309) appears to be weakly detected or absent in RGF-N2 cells, when compared to RGF cells and primary isolated aPF cells. Expression of G protein-coupled bile acid receptor 1 (Gpbar1/Tgr5) mRNA was observed in primary isolated aPF cells but not in RGF and RGF-N2 cells. Separately, expression of markers for other parenchymal and non-parenchymal liver cell types was studied, and showed that RGF and RGF-N2 cells express neither Albumin (Alb, hepatocytes) nor F4/80 (Emr1, macrophages) markers mRNAs, although Keratin 19 (Krt19, cholangiocytes) mRNA expression was detected (Fig. 1A). Expression of Mesothelin mRNA was also observed in both RGF and RGF-N2 cell lines with amplification of an additional splice variant that was unexpected (Fig. 1A). In addition, we studied and compared key fibrogenic portal myofibroblast genes such as, Acta2, Eln, Col1a1, Entpd2, and Nt5e by quantitative RT-PCR (Fig. 1B). We found that SV40-mediated immortalization did not significantly alter the expression of the analyzed genes, except for Acta2 gene that was decreased in both cell lines (approximately 200 times for RGF, and 100 times for RGF-N2) relatively to primary isolated aPF, nonetheless with still detectable expression. Second, the cellular origin or identity of RGF and RGF-N2 cell lines was further established, following analysis of total protein extract samples by immunoblot for SV40 large anti-peptide (Nt5e) markers. Mmp-9 mRNA expression was detected (Fig. 1A). Expression of Mesothelin mRNA was also observed in both RGF and RGF-N2 cell lines with amplification of an additional splice variant that was unexpected (Fig. 1A). In addition, we studied and compared key fibrogenic portal myofibroblast genes such as, Acta2, Eln, Col1a1, Entpd2, and Nt5e by quantitative RT-PCR (Fig. 1B). We found that SV40-mediated immortalization did not significantly alter the expression of the analyzed genes, except for Acta2 gene that was decreased in both cell lines (approximately 200 times for RGF, and 100 times for RGF-N2) relatively to primary isolated aPF, nonetheless with still detectable expression. Second, the cellular origin or identity of RGF and RGF-N2 cell lines was further established, following analysis of total protein extract samples by immunoblot for expression of several proteins including simple epithelium keratins, Gfap, α-SMA, Elastin, Pdgfrβ and Egfr (Fig. 2). Immunoblot assays show that RGF and RGF-N2 cells express no cyto-keratin proteins, suggesting that these cell lines unambiguously derive from hepatic cells distinct from cholangiocytes (Fig. 2A). Additionally, Gfap protein expression was gradually lost with continuous passaging steps (Fig. 2A). Protein expression of myofibroblast-specific α-SMA and Pdgfrβ markers was observed, as well as the portal (myo)fibroblast-specific marker Elastin (Fig. 2B). Furthermore, immunofluorescence microscopy experiments show that RGF and RGF-N2 cells express α-SMA and Elastin within the cytoplasm, and Ntpdase2 and Cd73 at the plasma membrane (Fig. 3). As expected, RGF and RGF-N2 cells also express SV40 large antigen, which exhibits an expected exclusive nuclear localization (Fig. 3). Taken together, these results strongly indicate that both RGF and RGF-N2 cell lines express myofibroblast-specific markers and, do not derive from hepatocytes, hepatic stellate cells or cholangiocytes. Third, RGF and RGF-N2 cells were tested for DNA transfectability with an expression vector for monomeric green fluorescent protein (mGFP) with commercially available Fugene6 and Lipofectamine2000 reagents, according to manufacturer’s instructions. Immunofluorescence
microscopy experiments indicate that DNA transfer is achievable in both RGF and RGF-N2 cells using Fugene6 reagent (DNA/reagent 1:3 ratio tested), as mGFP expression in transfected cells is clearly observed (Fig. 4). In contrast, transfection assays with lipid-based Lipofectamine2000 reagent were unsuccessful in the selected experimental conditions (DNA/reagent 1:6 ratio tested, not shown). These results demonstrate that DNA transfer can be successfully achieved in both RGF and RGF-N2 cell lines. Fourth, the capacity of RGF and RGF-N2 cells to inhibit ductular proliferation was examined, as a previous report by our group showed that loss of Ntpdase2 expression in primary isolated aPF culture allows increased bile duct cell proliferation in a co-culture assay[21]. Furthermore, regulation of bile duct cell proliferation could be restored, if Ntpdase2 expression was re-established in activated PF[21]. Because, RGF and RGF-N2 cells have been immortalized in an “early activation” step, at which Ntpdase2 expression was still observable, it is plausible that both cell lines still possess the ability to block bile ductular proliferation. Therefore, this hypothesis was tested, using an experimental setup similar to the one previously described above. Indeed, co-culture assays demonstrate that both RGF and RGF-N2 cell lines can significantly reduce the proliferation rate of bromodeoxyuridine-labeled Mz-ChA-1 cholangiocytes in vitro with the same relative efficacy (Fig. 5), comparable to cultured primary isolated aPF (not shown).

**Discussion**

We report, in the present paper, the generation and functional characterization of two novel rat SV40-immortalized PF cell lines: RGF and RGF-N2. The RGF cell line was established by immortalization of cultured primary isolated aPF, while the RGF-N2 cell line was established by immortalization of cultured Ntpdase2-sorted primary isolated aPF. We performed preliminary studies to screen RGF and RGF-N2 cell lines for expression of common liver myofibroblast-associated genes. RGF and RGF-N2 express classical pan–myofibroblast αSMA (mRNA and protein), Pdgf receptor-β (mRNA and protein), type I Collagen α1 (mRNA), and PF-specific Elastin (mRNA and protein), type XV Collagen α1 (mRNA) and Fibulin-2 (mRNA), an expression pattern also observed in cultured primary isolated aPF (mRNA). Importantly, RGF and RGF-N2 cell lack expression of HSC-specific Desmin and Lrat marker mRNAs. Both cell lines do express cholangiocyte Keratin 19 mRNA, although no corresponding protein expression was noted by immunoblot analysis, using a polyclonal pan cytoKeratin antibody (Fig. 2) and a monoclonal Keratin 7 (Keratin 19 partner) antibody (not shown). We also observed differences in: 1) Vegfr2 mRNA expression between RGF (detected) and RGF-N2 (absent or weak) cell lines; 2) of Gpbar1 mRNA expression between cultured primary isolated aPF (detected) and RGF and RGF-N2 cell lines (weak); and 3) Gfap mRNA expression between cultured primary isolated aPF (absent) and RGF and RGF-N2 cell lines (detected). In both cases of Vegfr2 and Gpbar1 genes, we did not investigate the corresponding protein expression, for lack of reliable immunoblot-capable antibodies. In the case of Gfap gene, Gfap protein was expressed in early passages after immortalization but gradually decreased (after 45 passages). We sought to test the achievability of DNA transfer in RGF and RGF-N2 cell lines, which is an important feature to perform functional studies. Using a commercially-available transfection reagent, both RGF and RGF-N2 were found to be transfectable with DNA (and likely RNA, even though it was not tested here). Lastly, we demonstrated Ntpdase2-expressing RGF and RGF-N2 cell lines have the ability to block proliferation of Mz-ChA-1 cholangiocarcinoma cells, as was previously demonstrated for rat cultured primary isolated aPF. Importantly, we obviously cannot claim that the described polyclonal cell lines are functionally representative of all types of activated liver myofibroblasts originating from portal areas of the fibrosing liver. Specificity and reliability of cell markers, currently used to define cellular sources of liver
myofibroblasts including portal fibroblasts, are still debated[1,4,33,34]. It is well possible that discrepancies in cell marker expression between species[35–38], as well as activation stage[8] may exist. Thus, these are critical parameters that need careful consideration if comparisons are to be made between RGF and RGF-N2 cell lines and portal liver myofibroblasts from other origins (likely mouse and human species). In summary, we have generated two novel cellular models for the in vitro study of liver portal (myo)fibroblasts functions.

Supporting Information

S1 Fig. Cultured primary isolated portal fibroblasts, and both immortalized RGF and RGF-N2 cells by phase contrast illumination microscopy. (TIF)

S2 Fig. Characterization of primary isolated portal fibroblasts by cell sorting. (TIF)

Author Contributions

Conceived and designed the experiments: MF JAD. Performed the experiments: MF JRG EGL ALG. Analyzed the data: MF JRG EGL JAD. Contributed reagents/materials/analysis tools: JS. Wrote the paper: MF JAD.

References

1. Wells RG. The portal fibroblast: not just a poor man's stellate cell. Gastroenterology. 2014; 147: 41–47. doi: 10.1053/j.gastro.2014.05.001 PMID: 24814904
2. Fausther M, Lavoie EG, Dranoff JA. Contribution of Myofibroblasts of Different Origins to Liver Fibrosis. Curr Pathobiol Rep. 2013; 1: 225–230. PMID: 23997993
3. Lemoinne S, Cadoret A, El Mourabit H, Thabut D, Housset C. Origins and functions of liver myofibroblasts. Biochim Biophys Acta. 2013; 1832: 948–954. doi: 10.1016/j.bbadis.2013.02.019 PMID: 23470555
4. Xu J, Liu X, Koyama Y, Wang P, Lan T, Kim IG, et al. The types of hepatic myofibroblasts contributing to liver fibrosis of different etiologies. Front Pharmacol. 2014; 5: 167. doi: 10.3389/fphar.2014.00167 PMID: 25100997
5. Dranoff JA, Wells RG. Portal fibroblasts: Underappreciated mediators of biliary fibrosis. Hepatology. 2010; 51: 1438–1444. doi: 10.1002/hep.23405 PMID: 20209607
6. Friedman SL. Evolving challenges in hepatic fibrosis. Nat Rev Gastroenterol Hepatol. 2010; 7: 425–436. doi: 10.1038/nrgastro.2010.97 PMID: 20585339
7. Mederacke I, Hsu CC, Troeger JS, Huebener P, Mu X, Dapito DH, et al. Fate tracing reveals hepatic stellate cells as dominant contributors to liver fibrosis independent of its aetiology. Nat Commun. 2013; 4: 2823. doi: 10.1038/ncomms2823 PMID: 24264436
8. Iwaisako K, Jiang C, Zhang M, Cong M, Moore-Morris TJ, Park TJ, et al. Origin of myofibroblasts in the fibrotic liver in mice. Proc Natl Acad Sci U S A. 2014; 111: E3297–3305. doi: 10.1073/pnas.140062111 PMID: 25074909
9. Xu L, Hui AY, Albanis E, Arthur MJ, O'Byrne SM, Blaner WS, et al. Human hepatic stellate cell lines, LX-1 and LX-2: new tools for analysis of hepatic fibrosis. Gut. 2005; 54: 142–151. PMID: 15591520
10. Schnabl B, Choi YH, Olsen JC, Hagedom CH, Brenner DA. Immortal activated human hepatic stellate cells generated by ectopic telomerase expression. Lab Invest. 2002; 82: 329–333. PMID: 11896211
11. Martucci RB, Zulikoski AL, Fortuna VA, Guaragna RM, Guma FC, Trugo LC, et al. Beta-carotene storage, conversion to retinoic acid, and induction of the lipocyte phenotype in hepatic stellate cells. J Cell Biochem. 2004; 92: 414–423. PMID: 15108365
12. Guo J, Hong F, Loke J, Yea S, Lim CL, Lee U, et al. A DDX5 S480A polymorphism is associated with increased transcription of fibrogenic genes in hepatic stellate cells. J Biol Chem. 2010; 285: 5428–5437. doi: 10.1074/jbc.M109.035295 PMID: 20022962
13. Vogel S, Piantedosi R, Frank J, Lalazar A, Rockey DC, Friedman SL, et al. An immortalized rat liver stellate cell line (HSC-T6): a new cell model for the study of retinoid metabolism in vitro. J Lipid Res. 2000; 41: 882–893. PMID:10828080

14. Greenwel P, Schwartz M, Rosas M, Peyrol S, Grimaud JA, Rojkind M. Characterization of fat-storing cell lines derived from normal and CCl4-cirrhotic livers. Differences in the production of interleukin-6. Lab Invest. 1991; 65: 644–653. PMID: 1753710

15. Kruglov EA, Jain D, Dranoff JA. Isolation of primary rat liver fibroblasts. J Investig Med. 2002; 50: 179–184. PMID: 12033282

16. Wen JW, Olsen AL, Perepelyuk M, Wells RG. Isolation of rat portal fibroblasts by in situ liver perfusion. J Vis Exp. 2012.

17. Dranoff JA, Kruglov EA, Robson SC, Braun N, Zimmermann H, Sévigny J. The ecto-nucleoside triphosphate diphosphohydrolase NTPDase2/CD39L1 is expressed in a novel functional compartment within the liver. Hepatology. 2002; 36: 1135–1144. PMID: 12395323

18. Dezso K, Jelnes P, Laszlo V, Baghy K, Bodor C, Paku S, et al. Thy-1 is expressed in hepatic myofibroblasts and not oval cells in stem cell-mediated liver regeneration. Am J Pathol. 2007; 171: 1529–1537. PMID: 17884967

19. Ye J, Coulouris G, Zaretskaya I, Cutcutache I, Rozen S, Madden TL. Primer-BLAST: a tool to design target-specific primers for polymerase chain reaction. BMC Bioinformatics. 2012; 13: 134. doi: 10.1186/1471-2105-13-134 PMID: 22708584

20. Knuth A, Gabbert H, Dippold W, Klein O, Sachsse W, Bitter-Suermann D, et al. Biliary adenocarcinoma. Characterisation of three new human tumor cell lines. J Hepatol. 1985; 1: 579–596. PMID: 4056357

21. Jhandier MN, Kruglov EA, Lavoie EG, Sevigny J, Dranoff JA. Portal fibroblasts regulate the proliferation of bile duct epithelia via expression of NTPDase2. J Biol Chem. 2005; 280: 22986–22992. PMID: 15799977

22. Friedman SL. Mechanisms of hepatic fibrogenesis. Gastroenterology. 2008; 134: 1655–1669. doi: 10.1053/j.gastro.2008.03.003 PMID: 18471545

23. Hinz B. Mechanical aspects of lung fibrosis: a spotlight on the myofibroblast. Proc Am Thorac Soc. 2012; 9: 137–147. doi: 10.1513/pats.201202-017AW PMID: 22802288

24. Henderson NC, Arnold TD, Katamura Y, Giacomini MM, Rodríguez JD, McCarty JH, et al. Targeting of alphav integrin identifies a core molecular pathway that regulates fibrosis in several organs. Nat Med. 2013; 19: 1617–1624. doi: 10.1038/nm.3282 PMID: 24216753

25. Iwaisako K, Brenner DA, Kisseleva T. What’s new in liver fibrosis? The origin of myofibroblasts in liver fibrosis. J Gastroenterol Hepatol. 2012; 27 Suppl 2: 65–68. doi: 10.1111/j.1440-1746.2011.07002.x PMID: 22320919

26. Bosselut N, Housset C, Marcelo P, Rey C, Burmester T, Vinh J, et al. Distinct proteomic features of two fibrogenic liver cell populations: hepatic stellate cells and portal myofibroblasts. Proteomics. 2010; 10: 1017–1028. doi: 10.1002/pmic.200900257 PMID: 20049859

27. Lemoine S, Cadoret A, Rautou PE, El Mourabit H, Ratziu V, Corpechot C, et al. Portal myofibroblasts promote vascular remodeling underlying cirrhosis formation through the release of microparticles. Hepatology. 2014.

28. Perepelyuk M, Terajima M, Wang AY, Georges PC, Janney PA, Yamauchi M, et al. Hepatic stellate cells and portal fibroblasts are the major cellular sources of collagen and lysyl oxidases in normal liver and early after injury. Am J Physiol Gastrointest Liver Physiol. 2013; 304: G605–G614. doi: 10.1152/ajpgi.00222.2012 PMID: 23328207

29. Tateaki Y, Ogawa T, Kawada N, Kohashi T, Arihiro K, Tateno C, et al. Typing of hepatic nonparenchymal cells using fibulin-2 and cytoglobin/STAP as liver fibrogenesis-related markers. Histochem Cell Biol. 2004; 122: 41–49. PMID: 15221412

30. Mezaki Y, Morii M, Hebiguchi T, Yoshikawa K, Yamaguchi N, Miura M, et al. Differential increases in the expression of intermediate filament proteins and concomitant morphological changes of transdifferentiating rat hepatic stellate cells observed in vitro. Acta Histochem Cytochem. 2013; 46: 137–143. doi: 10.1267/ahc.13007 PMID: 24194627

31. Li Z, Dranoff JA, Chan EP, Uemura M, Sevigny J, Wells RG. Transforming growth factor-beta and substrate stiffness regulate portal fibroblast activation in culture. Hepatology. 2007; 46: 1246–1256. PMID: 17625791

32. Friedman SL. Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiol Rev. 2008; 88: 125–172. doi: 10.1152/physrev.00013.2007 PMID: 18195085

33. Iwaisako K, Taura K, Koyama Y, Takemoto K, Asagiri M. Strategies to Detect Hepatic Myofibroblasts in Liver Cirrhosis of Different Etiologies. Curr Pathobiol Rep. 2014; 2: 209–215. PMID: 25401051
34. Wells RG. Portal Fibroblasts in Biliary Fibrosis. Curr Pathobiol Rep. 2014; 2: 185–190. PMID: 25599013

35. Cassiman D, Libbrecht L, Desmet V, Denef C, Roskams T. Hepatic stellate cell/myofibroblast subpopulations in fibrotic human and rat livers. J Hepatol. 2002; 36: 200–209. PMID: 11830331

36. Ijzer J, Roskams T, Molenbeek RF, Ultee T, Penning LC, Rothuizen J, et al. Morphological characterisation of portal myofibroblasts and hepatic stellate cells in the normal dog liver. Comp Hepatol. 2006; 5: 7. PMID: 17109742

37. Ramadori G, Saile B. Portal tract fibrogenesis in the liver. Lab Invest. 2004; 84: 153–159. PMID: 14688800

38. Hinz B, Phan SH, Thannickal VJ, Galli A, Bochaton-Piallat ML, Gabbiani G. The myofibroblast: one function, multiple origins. Am J Pathol. 2007; 170: 1807–1816. PMID: 17525249